ENDRA Life Sciences Inc.
NDRA
$3.49
-$0.02-0.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 940.60K | 3.66M | 714.60K | 1.51M | 1.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.47M | 4.30M | 1.51M | 2.23M | 2.78M |
| Operating Income | -1.47M | -4.30M | -1.51M | -2.23M | -2.78M |
| Income Before Tax | -1.04M | -4.15M | -2.35M | -2.23M | -2.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.04M | -4.15M | -2.35M | -2.23M | -2.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.04M | -4.15M | -2.35M | -2.23M | -2.78M |
| EBIT | -1.47M | -4.30M | -1.51M | -2.23M | -2.78M |
| EBITDA | -1.46M | -4.29M | -1.50M | -2.22M | -2.77M |
| EPS Basic | -1.86 | -7.69 | -9.54 | -142.99 | -- |
| Normalized Basic EPS | -1.16 | -4.81 | -5.96 | -89.37 | -- |
| EPS Diluted | -1.86 | -7.69 | -9.54 | -142.99 | -- |
| Normalized Diluted EPS | -1.16 | -4.81 | -5.96 | -89.37 | -- |
| Average Basic Shares Outstanding | 557.60K | 539.60K | 246.80K | 15.60K | -- |
| Average Diluted Shares Outstanding | 557.60K | 539.60K | 246.80K | 15.60K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |